Abstract
Insulin is increasingly unaffordable in the United States. Despite the fact that insulin was developed almost one hundred years ago, the insulin market is dominated by only three companies, and there continue to be no biosimilar competitors in the United States. Insulin has been insulated from competition for years. However, insulin is unlike many other high-priced prescription drugs and faces several unique legal, regulatory, and practical challenges to permitting increased competition in the market. This Article examines the barriers to competition in the insulin market, considering the challenges surrounding regulatory approval, pricing, interchangeability, trade secrets, and anti-competitive behavior. In doing so, this Article attempts to explain why there is such limited competition in the insulin market and raises considerations in developing competition-based proposals to address access to affordable insulin in the United States.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
